The role of ablative treatment in differentiated thyroid cancer management

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Young RL, Oertel JE, et al. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltimore). 1977;56(3):171–196.
   PubMed Web of Science ®Google Scholar
• Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154(6):787–803.
   PubMed Web of Science ®Google Scholar
• Davies L, Morris LG, Haymart M, et al. American association of clinical endocrinologists and American college of endocrinology disease state clinical review: the increasing incidence of thyroid cancer. Endocr Pract. 2015;21(6):686–696.
   PubMed Web of Science ®Google Scholar
• Sawka AM, Thephamongkhol K, Brouwers M, et al. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89(8):3668–3676.
   PubMed Web of Science ®Google Scholar
• Sawka AM, Brierley JD, Tsang RW, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am. 2008;37(2):457–80, x.
   PubMed Web of Science ®Google Scholar
• Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16(12):1229–1242.
   PubMed Web of Science ®Google Scholar
• Jonklaas J, Cooper DS, Ain KB, et al. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid. 2010;20(12):1423–1424.
   PubMed Web of Science ®Google Scholar
• Schvartz C, Bonnetain F, Dabakuyo S, et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab. 2012;97(5):1526–1535.
   PubMed Web of Science ®Google Scholar
• Lamartina L, Durante C, Filetti S, et al. Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. J Clin Endocrinol Metab. 2015;100(5):1748–1761.
   PubMed Web of Science ®Google Scholar
• Spencer CA, Lopresti JS. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat Clin Pract Endocrinol Metab. 2008;4(4):223–233.
   PubMedGoogle Scholar
• Haugen BR, Alexander EK, Bible KC, et al. 2015. American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.
   PubMed Web of Science ®Google Scholar
• Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81(Suppl 1):1–122.
   PubMed Web of Science ®Google Scholar
• Pacini F, Castagna MG, Brilli L, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v214–9.
   PubMed Web of Science ®Google Scholar
• Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214.
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418–428.
   PubMed Web of Science ®Google Scholar
• Verburg FA, Mader U, Reiners C, et al. Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patients. J Clin Endocrinol Metab. 2014;99(12):4487–4496.
   PubMed Web of Science ®Google Scholar
• Jung TS, Kim TY, Kim KW, et al. Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma. Endocr J. 2007;54(2):265–274.
   PubMed Web of Science ®Google Scholar
• Ibrahimpasic T, Nixon IJ, Palmer FL, et al. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer–is there a need for radioactive iodine therapy? Surgery. 2012;152(6):1096–1105.
   PubMed Web of Science ®Google Scholar
• Rosario PW, Mourao GF, Siman TL, et al. A low postoperative nonstimulated serum thyroglobulin level excludes the presence of persistent disease in low-risk papillary thyroid cancer patients: implication for radioiodine indication. Clin Endocrinol (Oxf). 2015;83(6):957–961.
   PubMed Web of Science ®Google Scholar
• Vaisman A, Orlov S, Yip J, et al. Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. Head Neck. 2010;32(6):689–698.
   PubMed Web of Science ®Google Scholar
• Nascimento C, Borget I, Troalen F, et al. Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation. Eur J Endocrinol. 2013;169(5):689–693.
   PubMed Web of Science ®Google Scholar
• Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184–199.
   PubMed Web of Science ®Google Scholar
• Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015;33(1):42–50.
   PubMed Web of Science ®Google Scholar
• George JR, Henderson YC, Williams MD, et al. Association of TERT promoter mutation, but not BRAF mutation, with increased mortality in PTC. J Clin Endocrinol Metab. 2015;100(12):E1550–9.
   PubMed Web of Science ®Google Scholar
• Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309(14):1493–1501.
   PubMed Web of Science ®Google Scholar
• Melo M, Da Rocha AG, Vinagre J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014;99(5):E754–65.
   PubMed Web of Science ®Google Scholar
• Liu R, Xing M. TERT promoter mutations in thyroid cancer. Endocr Relat Cancer. 2016;23(3):R143–55.
   PubMed Web of Science ®Google Scholar
• Yang X, Li J, Li X, et al. TERT promoter mutation predicts radioiodine refractory in distant metastatic differentiated thyroid cancer. J Nucl Med. 2017 Feb;58(2):258–265.
   PubMed Web of Science ®Google Scholar
• Mallick U, Harmer C, Hackshaw A, et al. Iodine or not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo. Clin Oncol (R Coll Radiol). 2012;24(3):159–161.
   PubMed Web of Science ®Google Scholar
• Verburg FA, Aktolun C, Chiti A, et al. Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016;43(6):1001–1005.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366(18):1663–1673.
   PubMed Web of Science ®Google Scholar
• Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366(18):1674–1685.
   PubMed Web of Science ®Google Scholar
• Molinaro E, Giani C, Agate L, et al. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity 131I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. J Clin Endocrinol Metab. 2013;98:2693–2700.
   PubMed Web of Science ®Google Scholar
• Castagna MG, Cevenini G, Theodoropoulou A, et al. Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. Eur J Endocrinol. 2013;169(1):23–29.
   PubMed Web of Science ®Google Scholar
• Mujammami M, Hier MP, Payne RJ, et al. Long-term outcomes of patients with papillary thyroid cancer undergoing remnant ablation with 30 milliCuries radioiodine. Thyroid. 2016;26(7):951–958.
   PubMed Web of Science ®Google Scholar
• Bal CS, Kumar A, Pant GS. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab. 2004;89(4):1666–1673.
   PubMed Web of Science ®Google Scholar
• Welsh L, Powell C, Pratt B, et al. Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancer. J Clin Endocrinol Metab. 2013;98(5):1819–1825.
   PubMed Web of Science ®Google Scholar
• Castagna MG, Cantara S, Pacini F. Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients. J Endocrinol Invest. 2016;39(10):1087–1094.
   PubMed Web of Science ®Google Scholar
• Miguel M, Gracinda C, Francisco C, et al. Radiotherapy: radioiodine and external beam irradiation treatment of differentiated thyroid carcinomas. In: Clinical management of thyroid cancer. Future Medicine Ltd; 2013. p. 78–92. eBook. ISBN: 978-1-78084-303-2.
   Google Scholar
• Remy H, Borget I, Leboulleux S, et al. 131I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med. 2008;49(9):1445–1450.
   PubMed Web of Science ®Google Scholar
• Borget I, Bonastre J, Catargi B, et al. Quality of life and cost-effectiveness assessment of radioiodine ablation strategies in patients with thyroid cancer: results from the randomized phase III ESTIMABL trial. J Clin Oncol. 2015;33(26):2885–2892.
   PubMed Web of Science ®Google Scholar
• Sawka AM, Ibrahim-Zada I, Galacgac P, et al. Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: a systematic review. Thyroid. 2010;20(10):1129–1138.
   PubMed Web of Science ®Google Scholar
• Tala Jury HP, Castagna MG, Fioravanti C, et al. Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. J Clin Endocrinol Metab. 2010;95(1):230–237.
   PubMed Web of Science ®Google Scholar
• Sawka AM, Thabane L, Parlea L, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid. 2009;19(5):451–457.
   PubMed Web of Science ®Google Scholar
• Rubino C, De Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89(9):1638–1644.
   PubMed Web of Science ®Google Scholar
• Taieb D, Sebag F, Farman-Ara B, et al. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2010;95(7):3283–3290.
   PubMed Web of Science ®Google Scholar